New Oral Treatment for Relapsing Multiple Sclerosis Shows Promise

Dimethyl Fumarate Demonstrates Efficacy in Reducing Disease Activity

Study Published in Neurology Journal

Düsseldorf, Germany - A promising new oral therapy has been shown to effectively reduce disease activity and progression in patients with relapsing multiple sclerosis (MS), according to a study published in the journal Neurology.

The therapy, dimethyl fumarate (DMF), is a novel oral medication that has been investigated for its potential in treating MS. The study, conducted by researchers at the WEB Neurology University Hospital Düsseldorf in Germany, evaluated the efficacy and safety of DMF in patients with relapsing-remitting MS.

The results of the study demonstrated that DMF significantly reduced relapse rates and slowed disease progression. Additionally, the therapy was found to be well-tolerated, with a favorable safety profile. The findings suggest that DMF may be a promising new treatment option for patients with relapsing MS.